Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors

Conclusions The RD for this combination is PM01183 3.0  mg FD (or 1.6 mg/m2)/gemcitabine 800  mg/m2 d1,8 q3wk. This schedule is well tolerated and has antitumor activity in several advanced solid tumor types.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research